<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79936">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064764</url>
  </required_header>
  <id_info>
    <org_study_id>Symplicity AF</org_study_id>
    <nct_id>NCT02064764</nct_id>
  </id_info>
  <brief_title>Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation</brief_title>
  <acronym>Symplicity AF</acronym>
  <official_title>Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Atrial Fibrillation Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Atrial Fibrillation Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the feasibility of performing both renal
      nerve denervation and pulmonary vein isolation on the same patient with the intent of
      characterizing both safety and effectiveness in a paroxysmal and persistent atrial
      fibrillation population with hypertension. To assess safety, the study will measure the
      occurrence of a composite safety endpoint and, to assess effectiveness, the study will
      measure freedom of chronic treatment failure through a minimum of six months of follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety composite events</measure>
    <time_frame>Up to one or six months post procedure depending on the event</time_frame>
    <description>The objective characterizes the rate of safety composite events, adjudicated as a serious adverse event, within each of the two study arms and also characterizes the difference in the rates between study arms. Each event in the composite has its own time frame, either one month or six months post procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of chronic treatment success between study arms</measure>
    <time_frame>Minimum of six months</time_frame>
    <description>Chronic treatment success is freedom from chronic treatment failure. Chronic treatment failure is defined as the occurrence of either a documented episode of AF lasting 30 seconds or longer or an intervention for AF.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Cryoablation only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein isolation plus renal never denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renal nerve denervation</intervention_name>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <other_name>Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <arm_group_label>Cryoablation only</arm_group_label>
    <arm_group_label>Cryoablation and renal nerve denervation</arm_group_label>
    <other_name>Arctic Front Advance™ Cardiac Cryoablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Drug refractory recurrent symptomatic paroxysmal or persistent atrial fibrillation

          -  Office-based systolic blood pressure of ≥150 mm Hg based despite treatment with 2 or
             more antihypertensive medications of different classes (one of these must be a
             diuretic)

          -  Age 18 years to 80 years old.

        Key Exclusion Criteria:

          -  Renal artery anatomy that is ineligible for treatment including: Lacks at least one
             renal artery for each kidney with ≥3 mm diameter and minimum treatable length per the
             Spyral Instructions for Use, Renal artery stenosis (&gt;50%) or renal artery aneurysm in
             either renal artery, A history of prior renal artery intervention including balloon
             angioplasty or stenting, Renal artery which contain calcification which does not
             allow at least four radio frequency ablations to be delivered , Diffuse fibromuscular
             dysplasia (FMD) or FMD which does not allow at least four radio frequency ablations
             to be delivered; FMD defined as visible beading of the artery on angiography ,
             Unilateral kidney.

          -  Estimated Glomerular Filtration Rate of &lt;30 mL/min/1.73m2.

          -  Pregnant, nursing or planning to be pregnant. (Female participants of childbearing
             potential must have a negative serum or urine human chorionic gonadotropin (hCG)
             pregnancy test prior to angiography).

          -  Currently enrolled or plans to participate in a potentially confounding drug or
             device trial during the course of this study. Co-enrollment in concurrent studies is
             allowed when documented pre-approval is obtained from the Medtronic study manager.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Chinitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Wigert</last_name>
    <phone>763-526-2802</phone>
    <email>dana.wigert@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Simmons</last_name>
    <phone>763-526-2353</phone>
    <email>kristy.simmons@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Medical Group-Cardiology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P O'Neill, MD</last_name>
      <phone>916-453-2682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jagmeet Singh, MD</last_name>
      <phone>917-726-4662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Silver, MD</last_name>
      <phone>781-744-8863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPHS-Marquette</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolph Evonich, MD</last_name>
      <phone>906-225-7190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Mittal, MD</last_name>
      <phone>201-447-8453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Chinitz, MD</last_name>
      <phone>212-263-7149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Augostini, MD</last_name>
      <phone>614-293-4967</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sangrigoli, MD</last_name>
      <phone>215-345-2556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Saba, MD</last_name>
      <phone>412-648-6024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Foundation</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Johnson, MD</last_name>
      <phone>901-271-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Fellows, MD</last_name>
      <phone>206-341-1111</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
